This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day. Failure to maintain improvement in psychosocial functioning, on the basis of the Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey, was defined as loss of at least 50% of the improvement from acute-phase baseline achieved during acute and continuation treatment or dose escalation of more than 225 mg/day. The probability of remaining well (no failure to maintain improvement in functioning) was significantly higher through 12-month maintenance treatment for patients treated with venlafaxine ER 75-225 mg/day versus placebo Social Adjustment Scale-Self-Report, Life Enjoyment Scale, Quality of Life Enjoyment and Satisfaction Questionnaire, and Short-Form Health Survey component summary scores (all P≤0.0351). Effects of up to 20 months of treatment with venlafaxine ER 75-225 mg/day on psychosocial functioning were consistent with the results for venlafaxine ER 75-300 mg/day.

中文翻译：

---

在PREVENT研究中，与安慰剂相比，文拉法辛缓释剂的长期功能和社会心理结果为75-225 mg /天。

这项事后分析评估了使用文拉法辛缓释（ER）75-225 mg /天或安慰剂治疗的复发性重度抑郁症患者的长期心理状况。对10周文拉法辛ER 75-300 mg /天治疗有反应并通过6个月持续治疗维持反应的患者被随机分配至文拉法辛ER或安慰剂维持期治疗。在接受12个月维持治疗期间，同时接受高达225 mg /天的文拉法辛ER的患者，对急性和持续性文拉法辛ER 75-225 mg /天的治疗者的数据进行了分析。根据社会调整量表-自我报告，生活享受量表，生活享受和满意度调查表的质量以及简短健康调查，未能保持社会心理功能的改善，定义为急性和持续治疗或剂量增加超过225 mg / day所达到的急性期基线改善的至少50％丧失。相较于安慰剂社交调整量表-自我报告，生活享受量表，质量，使用文拉法辛ER 75-225 mg /天治疗的患者，通过12个月维持治疗后，保持良好状态（没有保持功能改善的可能性）的可能性显着更高生活满意度和满意度调查表，以及简短健康调查组成部分的总分（均P≤0.0351）。使用文拉法辛ER 75-225 mg /天长达20个月的治疗对社会心理功能的影响与文拉法辛ER 75-300 mg /天的结果一致。